Glenmark Pharma USA to Launch Sodium Phosphates Injection in April 2026

Glenmark Pharmaceuticals Inc., USA will begin distribution of its Sodium Phosphates Injection USP vials in April 2026.
This launch targets a US market segment that generated approximately $66.8 million in sales for the 12 months ending December 2025.

Reader Takeaway: Glenmark expands US injectables with new launch; limited indications may temper market capture.

What just happened (today’s filing)

Glenmark Pharmaceuticals Inc., USA, announced it will launch its Sodium Phosphates Injection USP vials in April 2026.

The product includes three presentations: 15 mM P/5 mL, 45 mM P/15 mL, and 150 mM P/50 mL Single-Dose Vials.

These vials are bioequivalent and therapeutically equivalent to Hospira, Inc.'s reference listed drug, Sodium Phosphates Injection USP (NDA 018892).

Why this matters

The introduction of Sodium Phosphates Injection USP is set to broaden Glenmark's product portfolio in the US market.

It aligns with the company's strategy to offer affordable and quality treatment alternatives, particularly within the US institutional channel.

The backstory (grounded)

Glenmark Pharmaceuticals has been actively expanding its US presence with new product launches. In November 2025, its US subsidiary announced the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, entering a market with approximately $63.8 million in annual sales.

This aligns with Glenmark's broader 'Glenmark 3.0' strategy, which aims to become a leading global innovation-driven company by expanding its branded and specialty product portfolio and growing its US generic business through new injectables.

What changes now

• Glenmark will offer a new range of Sodium Phosphates Injection USP vials in the US market.
• The company expands its presence in the critical US institutional channel.
• This launch contributes to Glenmark's strategy of providing affordable, bioequivalent pharmaceutical alternatives.

Risks to watch

Glenmark's product is approved only for specific indications listed in its label. This contrasts with the broader market sales data of approximately $66.8 million, which pertains to all approved indications of the reference listed drug, potentially limiting its market penetration and revenue generation.

Glenmark Pharmaceuticals has also faced significant regulatory challenges, including US FDA warning letters related to manufacturing quality issues and recalls for other products, raising ongoing concerns about compliance at its facilities.

Peer comparison

Glenmark competes in the US generics and injectables market with major players such as Viatris, Teva Pharmaceutical Industries, and Dr. Reddy's Laboratories.

These companies also have substantial offerings in the US generics space, vying for market share with similar product types.

Context metrics (time-bound)

• The US market for Sodium Phosphates Injection USP generated approximately $66.8 million in sales for the 12-month period ending December 2025.

What to track next

• Monitor the actual distribution commencement by Glenmark Pharmaceuticals Inc., USA, in April 2026.
• Observe market reception and the initial sales performance of the new Sodium Phosphates Injection USP product line.
• Track any updates on Glenmark's manufacturing compliance and regulatory status with the US FDA, given its past challenges.
• Watch for market share capture and competitive responses from peers in the US injectables segment.